Business Context and Reporting Period
This Form 6-K filing by AC Immune SA reports the results of the Annual Ordinary Shareholders' Meeting held on June 26, 2020. The company is a foreign private issuer based in Lausanne, Switzerland, focused on developing treatments for neurodegenerative diseases.
Key Financial Metrics
The filing references the 2019 financial year results approved by shareholders:
- 2019 Profit: KCHF 45,169 (45.169 million CHF).
- Accumulated Losses (Pre-2019): KCHF 107,320.
- Accumulated Losses (Post-2019): KCHF 62,151 (after applying the 2019 profit).
The filing does not provide specific data on revenue, operating cash flow, margins, debt levels, or liquidity ratios for the period.
Material Changes and Corporate Actions
Shareholders approved several material corporate actions and governance changes:
- Capital Structure: Approved an authorized share capital increase of up to CHF 290,000 (14,500,000 shares) valid until June 27, 2022.
- Debt Instruments: Approved a conditional capital increase of up to CHF 91,560.94 (4,578,047 shares) for conversion of bonds or similar debt instruments.
- Profit Appropriation: The 2019 profit was applied to reduce accumulated losses rather than being distributed as dividends.
Management Commentary, Compensation, and Risks
Compensation Approvals (FY 2020/2021):
- Board of Directors: Max non-performance cash compensation of CHF 565,000; max equity grant value of CHF 635,000.
- Executive Committee: Max non-performance cash compensation of CHF 2,778,000; max variable compensation of CHF 1,133,000; max equity grant value of CHF 3,496,000.
Governance: Shareholders approved the re-election of the Board of Directors (including Chairman Douglas Williams), the Statutory Auditors (PricewaterhouseCoopers SA), and the Independent Proxy (Reymond & Associés). The 2019 Annual Report and Financial Statements were approved.
Risks and Contingencies: The filing text does not explicitly detail new risks or contingencies beyond the standard corporate governance approvals.
Investor Verification Checklist
- Verify the full text of the 2019 Annual Report and IFRS Financial Statements (Exhibit 99.1 and related filings) to understand the composition of the KCHF 45,169 profit.
- Review the attached presentation (Exhibit 99.1) for details on the company's pipeline and cash runway, as this filing does not contain operational metrics.
- Confirm the terms of the authorized capital increase to assess potential dilution risks for existing shareholders.
- Check the 2019 Remuneration Report (Annex 99.3 to the March 30, 2020 Form 6-K) for detailed executive compensation breakdowns.